Bladder cancer treatment is advancing with new agents, especially for CIS refractory patients ineligible for cystectomy. Understanding patient selection and treatment sequencing is essential due to ...

Recent approvals of intravesical agents target CIS refractory patients ineligible for cystectomy, requiring specific pathological and BCG therapy criteria. Sequencing and reimbursement challenges ...

Focal therapy adoption is increasing, transitioning from skepticism to optimism, with more practitioners offering these treatments. Water vapor thermal therapy, adapted from BPH treatment, is under ...

Intermediate-risk bladder cancer management is evolving with new therapies, raising questions about treatment necessity and patient selection. BCG-unresponsive bladder cancer has four available ...

Advanced therapies for OAB are underutilized despite guideline changes allowing earlier use, no longer requiring multiple medication failures. Recent advancements in nerve modulation technology, ...

Bone scans have been the standard for staging metastatic prostate cancer due to their ability to detect bone metastases indirectly. PSMA-PET offers superior specificity and accuracy compared to bone ...

Posluma, a new PSMA-based tracer, will improve patient assessment for PSMA-based therapies like Lutetium-based theranostics. Dosimetry integration will enhance precision in identifying lesions and ...

“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," Scott Eggener, MD. Urologists should be open to innovative technologies and methodologies without ...

The meeting featured international societies and the first Spanish language abstract session, enhancing global collaboration in sexual medicine. Instructional courses covered topics like androgens, ...

New robotic systems like CMR and Medtronic's Hugo are entering the market, challenging Intuitive's dominance. Increased competition is expected to drive innovation and improve robotic surgical ...

Dave Winfield's MLB career spanned 22 years, starting with the San Diego Padres in 1973. He played for multiple teams, including the Yankees, Angels, Blue Jays, Twins, and Indians. Winfield founded ...

Intermediate-risk bladder cancer is gaining attention due to new therapies, raising questions about treatment necessity and patient selection. BCG-unresponsive bladder cancer has multiple therapeutic ...